Metabolic Blockade of Glycolysis Diminishes Autoreactive CD4 T-Cell Effector Responses in Type 1 Diabetes.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 42546221.
- Also identified by DOI 10.2337/db25-1152.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Our goal: limit glycolysis with 2-deoxyglucose (2-DG) in autoreactive CD4 T cells to delay spontaneous type 1 diabetes in NOD mice. Inhibition of glycolysis with 2-DG during autoreactive CD4 T-cell activation and differentiation decreased effector responses (interferon-γ), increased anergic markers (CD73, folate receptor 4), and delayed spontaneous type 1 diabetes in NOD mice. The effects of 2-DG on antigen-presenting cells resulted in a decrease in CD86 expression that may partly explain the induction of anergy. Inhibiting glycolysis is sufficient to diminish autoreactive CD4 T-cell responses and may be therapeutically applicable to other T cell-mediated inflammatory diseases.